Page 26 - Clinical Development News Today

/PRNewswire/ -- Centria Autism, a national provider of Applied Behavior Analysis (ABA) therapy for children with autism and their families, recently announced...

Last month, OSP was excited to write about One2Treat, a progressive startup specializing in digital health solutions, which has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.

From a child's chemistry set given to her by her grandfather to watching Open University maths programs, Karen Ooms seemed destined for a career in science.

Webinar Wednesdays is planned to be held on the last Wednesday of each month - starting on Wednesday, April 24th with the first webinar on the increasing prevalence of non-small cell lung cancer in...

/PRNewswire/ -- DelveInsights Stargardt Disease Market Insights report includes a comprehensive understanding of current treatment practices, Stargardt...

Ultrahuman, a force in wearable technology, has boldly planted its flag on American soil with the inauguration of UltraFactory.

Oncimmune Holdings plc, a prominent autoantibody profiling company catering to the pharmaceutical and biotechnology sectors, is expanding its horizons by delving into the realm of biomarkers for age-related diseases.

In a remarkable development, Front Line Medical Technologies Inc., an innovator in trauma care medical devices, has announced the attainment of CE marking for its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System).

Dublin, April 22, 2024 (GLOBE NEWSWIRE) -- The "BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering."BRII-835 + BRII-179 Market Size, Forecast, and Emerging Insight - 2032" report provides comprehensive insights about BRII-835 + BRII-179 for chronic hepatitis B in the seven major markets and China. A detailed picture of the BRII-835 + BRII-179 for chronic hepatitis B in the 7MM, i.e., the Unit...

Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.